Clinical Trial

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

Study acronym: OLINGUITO
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) and is safe to use. The study will also be comparing 200 mg with 100 mg filgotinib a day to see if the lower dose also helps to treat axSpA.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2023-03-14; most recent amendment 2025-12-03.
Status change: Recruiting → Active, Not Recruiting 2024-05-17
Status change: Not Yet Recruiting → Recruiting 2023-04-06
Trial Details
NCT Number NCT05785611
Lead Sponsor Alfasigma S.p.A.
Conditions Axial Spondyloarthritis
Enrollment 495 participants
Start Date 2023-04-05
Primary Completion 2024-09-04 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-04